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Summary
Due to inconsistency among reports on the therapeutic efficacy of melatonin, attention has been focused on the
development of more potent melatonin analogues with prolonged effects. Melatonergic drugs, ramelteon and
agomelatine have been effective in treating either sleep disorders or sleep disturbances associated with depressive
disorders. MT
1
 and MT
2
 melatonergic receptor agonist, ramelteon, was found effective in increasing total sleep
time and sleep efficiency, and in reducing sleep latency in patients with insomnia. No reduction in its efficacy was
found even after 6-12 months of continuous use. The mechanism of sleep promoting action of ramelteon is entirely
different from that of conventional hypnotics that are in use today. Ramelteon’s use is not associated with any
adverse effects even after six months to one year after its continuous usage. Another melatonergic drug, agomelatine,
has also been found effective in improving sleep efficiency and quality, and this action of agomelatine is suggested
to be one of the major mechanism by which agomelatine ameliorates depressive symptoms in patients with major
depressive disorders and bipolar disorders.
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1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine), first
identified by Lerner  et al. (1958), is the major
neurohormone secreted from the pineal gland mainly
during dark hours of the night and is released in higher
concentrations into the cerebrospinal fluid (Tricoire et al.,
2003). The circadian pattern of pineal melatonin secretion
is regulated by suprachiasmatic nucleus (SCN) of the
hypothalamus. A major portion of the SCN is projected to
the subparaventricular zone of the hypothalamus from
where fibers proceed to terminate in the areas involved
in sleep-wake regulation (Saper et al., 2005b). Sleep
regulation involves interaction of two separate mechanisms
namely an endogenous biological-clock that drives the
circadian-rhythm of sleep-wake cycle (process-C) and a
homeostatic process (process-S) that influences sleep-
propensity which is determined by the duration of previous
sleep episodes (Borbely, 1982). These two processes
interact continuously and determine the consolidated bout
of sleep at night and consolidated bout of wakefulness
during daytime. Melatonin has a role in sleep regulation,
since its nocturnal rise leads to “opening of the sleep gate”
and augmentation of sleep propensity (Dijk and Cajochen,
1997).
Importance of melatonin in both initiation and
maintenance of sleep has been demonstrated (Cajochen
et al., 2003). In diurnal animals and in human beings the
onset of melatonin secretion has been shown to coincide
with the timing of increase in nocturnal sleep propensity
(Lavie, 1997). Since melatonin has both hypnotic and
chronobiotic properties, it has been used for treatment of
age-related insomnia and other primary and secondary
insomnia (Zhdanova et al., 2001), and prolonged release
of melatonin preparations are also effective in treating
insomnias (Wilson et al., 2010).
Melatonin has also been used successfully for
treatment of sleep disturbances due to disruptions of the
circadian time keeping system like jet-lag, shift-work
disorder or delayed sleep phase syndrome (Arendt et al.,
1997; Srinivasan et al., 2010b). The high density of MT
1
and MT
2
 melatonin receptors in the hypothalamic SCN
confirms that melatonin regulates sleep and the sleep-
J Endocrinol  Reprod 16 (2012) 1 : 15-24 Review Article 15
wakefulness cycle by acting on both these receptors
(Reppert et al., 1994; Dubocovich et al., 2010).
As melatonin has a short-half life (less than 30
min) its efficacy in promoting and maintaining sleep has
not been uniform in the studies that have been undertaken
so far. Hence, the need for the development of melatonin
agonists with a longer duration of action on sleep regulatory
structures in the brain has been felt (Turek and Gillette,
2004). Recently, melatonergic chrono-hypnotic drug,
ramelteon, has been introduced for treatment of primary
insomnia and has been effective in improving sleep quality
and efficiency when compared to melatonin or slow
release preparations (Srinivasan et al., 2012).
2. Insomnia
Insomnia is a sleep disorder characterized by poor
quality of sleep with symptoms like difficulty in falling
asleep, frequent awakenings during night time, early
morning awakenings, etc., resulting in fatigue, decreased
memory, and impaired performance with a negative impact
on health and quality of life. It is most common among
elderly people and is the major cause for impairment of
physical and mental health (Van Someren, 2000). Nearly
30 to 40% of the adult population suffers from mild to
severe insomnia. The sequels of insomnia include fatigue,
reduced alertness, irritability and impaired concentration,
all these symptoms having a major negative impact on the
quality of life (Cricco et al., 2001; Bastien, 2011). Due to
its broad psychological and physiological impacts, insomnia
has social consequences like increased risk of accidents
and reduced productivity. Insomnia is treated with lifestyle
modifications like relaxation and cognitive therapies,
behavioral techniques like sleep hygiene (Montgomery and
Dennis, 2004), and pharmacologic interventions that
employ sedative-hypnotics of both benzodiazepine and non
benzodiazepine drugs (Wilson et al., 2010).
3. Melatonin and sleep
The role of melatonin in the control of sleep has
been investigated in both diurnal and nocturnal species.
Local injection of pharmacological doses of melatonin (1
to 50 µg) in the medial preoptic area of the rat
hypothalamus during daytime increased total sleep time
in a dose-dependent manner mainly by increasing non-
rapid eye movement (NREM) sleep (Mendelson, 2002).
Melatonin has been shown to induce sleep by altering the
functions of the GABA
A
-benzodiazepine receptor
complex (Golombek et al., 1996). In diurnal species
suppression of electrical activity in the SCN is suggested
as the possible mechanism by which melatonin regulates
sleep. This effect is absent in MT
1
 knockout mice showing
thereby the importance MT
1
 receptors in melatonin’s acute
inhibitory effects on SCN electrical activity (Liu et al.,
1997). The MT
1
 and MT
2
 melatonin receptor subtypes
are complementary in their actions and to some extent
mutually substitute for each other. The suppression of
neuronal activity by melatonin is one of the possible
mechanisms by which this hormone contributes to the
regulation of sleep.
As melatonin deficiency is suggested as a cause
rather than a marker for insomnia in the elderly,
melatonin replacement therapy has been advocated for
treating insomnia at the old age. Because melatonin is a
natural hypnotic it is suitable for long term use in elderly
people due to its low toxicity and limited side effect profile.
Melatonin replacement therapy has been beneficial in
treating elderly insomniacs since it significantly improved
total sleep time (TST) and sleep quality, and reduced sleep
onset latency (SOL) (Dollins et al., 1994; Garfinkel et al.,
1995; Zhdanova et al., 1995, 1996; Monti et al., 1999;
Brzezinski et al., 2005).
Reduced endogenous melatonin production seems
to be a prerequisite for effective exogenous melatonin
treatment of sleep disorders in the elderly. A meta-analysis
on the effects of melatonin in sleep disturbances at all
age groups (including young adults with presumably normal
melatonin levels) by one of the authors of this review,
revealed significant and clinically meaningful effects of
exogenous melatonin on sleep quality, efficiency and
latency (Brzezinski et al., 2005). However, another meta-
analytical study could not find melatonin as effective in
increasing sleep efficacy (SE) and reducing SOL in old
subjects (Buscemi et al., 2006).
The relationship between sleep disturbances and
low nocturnal melatonin production was investigated in a
large population of insomniacs aged 55 years or more.
Elderly insomniacs with sleep problems excreted 9.0 ±
8.3 µg of the urinary melatonin metabolite 6-
sulfatoxymelatonin per night, whereas age-matched
healthy controls excreted 18.1 ± 12.7 µg of 6-
sulfatoxymelatonin per night, and younger subjects
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excreted 24.2 ± 11.9 µg of 6-sulfatoxymelatonin per night.
It was also observed that half of the elderly insomniacs
excreted less than 8.0 µg of 6-sulfatoxymelatonin per night.
Within this subpopulation of 372 subjects, 112 had urinary
6-sulphatoxy melatonin values lower than 3.5 µg per night
(Dijk and Cajochen, 1997).
Studies carried out using 0.3-1 mg doses of
melatonin, that attained in circulation “physiological
melatonin levels”, have shown that melatonin reduced
sleep latency (SL) and increased SE when administered
to healthy human subjects during evening (Dollins et al.,
1994). However, in most studies higher doses of melatonin
(2-6 mg) were needed to be given to obtain the desired
effects. Brain imaging studies in awake subjects show
that melatonin modulates brain activity pattern to one that
of resembling actual sleep (Gorfine et al., 2006). Despite
clinical studies, the general efficacy of melatonin as a
sleep-promoting substance has been a subject of debate
(Mendelson, 1997). A possible explanation for this is that
administered melatonin doses are too low. The reported
lack of efficiency of melatonin could be related to the
extremely short-half life of the fast release melatonin
preparations, and this prompted the development of active
slow release formulations (Dalton et al., 2000). Circadin®,
a 2 mg-controlled release preparation of melatonin,
developed by Neurim (Tel Aviv, Israel) was approved by
the European Medicines Agency (EMEA) as a
monotherapy for short-term treatment of primary insomnia
of elderly subjects in 2007. Circadin®, a slow-release
melatonin preparation, has been shown to improve the
quality of sleep and morning alertness, to reduce SOL
and to ameliorate quality of life in middle-aged and elderly
insomniacs (Lemoine et al., 2007; Wade et al., 2011).
Generally, the poor melatonin excretors responded better
to melatonin replacement therapy than other insomniacs.
An unknown aspect of melatonin activity in brain with
regard to its hypnotic and chronobiotic activities is the
extent to which it desensitizes membrane MT
1
 and MT
2
receptors. Receptor desensitization is a normal process
in G-protein coupled receptors and, hence, it is expected
for MT
1
 and MT
2
 melatonin receptors also. But in a study
conducted on SCN neurons, neither in vivo studies (intra-
peritoneal or iontophoretic application of melatonin) nor
in vitro studies on SCN neuronal cells revealed
desensitization phenomenon (Ying et al., 1998). However,
desensitization phenomenon with melatonin on the
membrane receptor has been observed (Gerdin et al.,
2004). This raised doubt over using supra-physiological
doses of melatonin for treating patients with insomnia.
But melatonin receptor concentration has been shown to
increase in parallel with increase of melatonin
concentration (Masana et al., 2000). This finding cast doubt
on the theory of receptor desensitization phenomenon after
long-term use of either melatonin or its agonists.
4. Ramelteon: The melatonergic drug for
insomnia
Ramelteon (Rozerem®, Takeda Pharmaceuticals,
Japan) is a melatonergic hypnotic analog that has been
demonstrated in clinical trials to be effective and safe. It
is a tricyclic synthetic analog of melatonin with the
chemical name (S)-N-[2-(1,6,7,8-tetrahydro-2H-
indeno[5,4-b]furan-8-yl)-ethyl]propionamide (Fig. 1). In
2005 ramelteon was approved by the Food and Drug
Administration (FDA) for treatment of insomnia. It is a
selective agonist for MT
1
/MT
2
 receptors without
significant affinity for other receptor sites (Kato et al.,
2005; Miyamoto, 2009). In vitro binding studies have
shown that ramelteon affinity for MT
1
 and MT
2
 receptors
is 3-16 times higher than that of melatonin. The selectivity
of ramelteon for MT
1
 has been found to be greater than
that of MT
2
 receptors. The selectivity of MT
1
 receptors
by ramelteon suggests that it targets sleep onset more
specifically than melatonin itself (Cajochen, 2005).
Fig. 1: Melatonin and its agonists
4.1 Pharmacokinetics of ramelteon
Ramelteon is administered usually through oral
route and is absorbed rapidly by the gastrointestinal tract
(84%). The half-life of circulating ramelteon is in the range
of 1 to 2 hr which is much longer than that of melatonin.
The influence of age and gender on the pharmacokinetics
and pharmacodynamics of ramelteon were evaluated in
healthy volunteers (young: 18-34 yr; elderly: 63-79 yr) after
administration of a single dose of ramelteon. Compared
with young individuals, the clearance of ramelteon was
significantly reduced in elderly individuals. No significant
effect of gender was observed (Greenblatt et al., 2007).
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Ramelteon is metabolized mainly in the liver via
oxidation to hydroxyl and carbonyl groups and then
conjugated with glucuronide. Cytochrome P450 1A2 is
the major hepatic enzyme involved in ramelteon
metabolism. Four principal metabolites of ramelteon (M-
I, M-II, M-III, M-IV) have been identified. Among these,
M-II has been found to occur in a much higher
concentrations with systemic levels 20- to100-folds greater
than ramelteon itself. Although the activity of M-II is 30-
folds lower than that of ramelteon, its exposure exceeds
that of ramelteon by a factor of 30. Hence, it is suggested
that M-II may contribute significantly to the net clinical
effect of ramelteon intake (Miyamoto, 2009).
4.2 Mechanism of ramelteon sedative-
hypnotic action
Although MT
1
 and MT
2
 receptors are widely
distributed in the brain outside the SCN (Wu et al., 2006),
the high density of melatonin receptors in the SCN and
their relationship to the circadian pacemaker function and,
in particular, to sleep-wake cycle are highly suggestive of
the SCN melatonin receptor role in sleep regulation.
Ramelteon specificity for MT
1
 and MT
2
 melatonin
receptors indicates that ramelteon’s probable sleep-related
site of action is in the SCN (Fig. 2) (Liu et al., 1997).
Fig. 2 Mechanism of action of ramelteon.
A “sleep-switch” model to describe the regulation
of sleep-wakefulness was originally proposed by Saper
et al. (2005b). It consists of “flip-flop” reciprocal inhibitions
among sleep-associated activities in the ventrolateral
preoptic nucleus and wakefulness-associated activities in
the locus coeruleus, dorsal raphe and tuberomammilary
nuclei. The SCN has an active role in promoting
wakefulness as well as in promoting sleep and this depends
upon a complex neuronal network and a number of
neurotransmitters released from networks of GABA,
glutamate, arginine vasopressin, somatostatin, etc.
(Kalsbeek et al.,  2006; Raghunandanan and
Raghunandanan, 2006).
Ramelteon may accelerate sleep onset by
influencing the hypothalamic sleep switch downstream
from the SCN in the same way as melatonin. Ramelteon
promotes sleep onset through inhibition of SCN electrical
activity and the consequent inhibition of circadian wake
signal thereby activating the specific sleep-circuit pathway
(Saper et al., 2005a).
4.3 Clinical studies on ramelteon in insomnia
The first study on the effects of ramelteon on
sleep was conducted by Roth and co-workers in 2005. In
this study involving 117 patients (16 to 64 yr), drawn from
13 centers in Europe, the efficacy, safety and dose
response of ramelteon were examined. Each patient was
randomized to a dose sequence of 4, 8, 16 or 32 mg of
ramelteon. All doses of ramelteon produced a statistically
significant reduction in latency to persistent sleep (LPS)
and increased TST as shown by polysomnography (PSG)
(Roth et al., 2005).
In a  follow-up study, the same group of
investigators administered ramelteon to 829 patients (>65
years) for a period of five weeks. In this double blind
study ramelteon, at a dose of 4-8 mg/day, brought about a
significant reduction in SOL (16% to 35%). TST was
increased by both doses of ramelteon (Roth et al., 2006).
In another randomized, multicenter double-blind, placebo-
controlled crossover study in 107 patients and associating
PSG, ramelteon was administered in doses of 4-32 mg/
day. The treatment decreased LPS and increased TST
significantly (Erman et al., 2006).
A short term evaluation of the efficacy of
ramelteon was performed in 100 elderly subjects by
administering 4 and 8 mg doses in a two night/three day
period crossover design. LPS decreased, and TST and
SE augmented as compared to placebo (Roth et al, 2007).
Likewise, the efficacy of ramelteon in reducing SOL and
in increasing TST and SE was evaluated in 371 patients
administered with 8 or 16 mg of ramelteon for 5 weeks in
a double-blind placebo controlled study. The results
confirmed the effect of ramelteon to reduce SOL and
increase SE and TST (Zammit et al., 2007).
Ramelteon hypnotic action (at an 8 mg dose) was
so rapid that it caused significant reductions in SOL within
a week (63% for ramelteon vs. 39.7% for placebo,
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p< 0.001). This reduction in LPS was sustained throughout
the 5 weeks of study (63 and 65.9% ramelteon vs. 41.2
and 48.9% placebo at the end of the 3rd and 5th week,
respectively) (Mini et al., 2008). Reduction in LPS after
ramelteon treatment was found in healthy human subjects
in a 6-week long study using an 8 mg dose; in this study
on healthy human subjects ramelteon increased TST also
(Dobkin et al, 2009). In another 6 months study performed
in 451 adults suffering from chronic insomnia, drawn from
different centers across the globe (mainly USA, Europe,
Russia and Australia), ramelteon consistently reduced LPS
when compared to placebo (Mayer et al., 2009). The
baseline LPS decreased from 70.7 to 32.0 minutes at week
one and this reduction in LPS was maintained at months
1, 3, 5 and 6. No adverse effects, like next morning
residual effects, rebound insomnia or withdrawal effects,
were noticed (Mayer et al., 2009).
In a double-blind placebo controlled study
involving large number of Japanese patients with chronic
insomnia (n=1130) the efficacy and safety of 4 and
8 mg ramelteon doses were evaluated. No statistically
significant differences were found in subjective SOL of
patient treated with 4 mg ramelteon compared to the
placebo group, while a significant increase in TST and a
decrease in SOL were observed with 8 mg ramelteon
(Uchimura et al., 2011).
The same investigators evaluated the efficacy and
safety of ramelteon in 190 Japanese adults with chronic
insomnia treated for a period of 24 weeks. TST
significantly increased with ramelteon 8 mg/day dose and
this was maintained for 20 weeks. In this study ramelteon
was well tolerated and it did not cause residual effects,
rebound insomnia, withdrawal symptoms or dependence
even after 24 weeks of continuous treatment (Uchiyama
et al., 2011). In all clinical studies undertaken so far to
evaluate the efficacy and safety of ramelteon in various
doses ranging from 4 to 32 mg/day in patients with chronic
insomnia, the drug reduced SOL and increased sleep duration
(Table 1). Besides acting as a sedative-hypnotic drug,
ramelteon also exhibited chronobiotic properties.
Dose 
(mg/day) 
Duration of 
administration 
Number of insomnia 
patients 
Sleep onset latency 
(SOL) / latency to 
persistent sleep (LPS) 
Sleep efficacy  
and quality 
Total sleep time Reference 
4, 8, 16  
and 32 
 
2 days  107  
(mean age: 37.7 yrs) 
 
Reduction in LPS 
(P<0.001) 
Increased 
 
Increased (P<0.05) Erman et al., 2006 
4 and 8 5 weeks  829  
(mean age: 72.4 yrs) 
Reduced SOL Enhanced  Increased at the end 
of first week, third 
week and fifth week 
Roth et al., 2006  
4 5 weeks 100 elderly patients Reduced LPS 
(P<0.001) 
Increased Increased  Roth et al., 2007 
8 and 16 5 weeks 371 patients with 
chronic insomnia  
Reduced SOL Increased Increased at all  
doses 
Zammit et al., 2007 
8 and 16 5 weeks  289 patients with 
chronic insomnia 
(mean age: 65 yrs) 
Reduced LPS 
(P=0.004) 
Increased Increased (P=0.009) Zammit et al., 2009  
8  5 weeks 270 patients with 
chronic insomnia  
63% reduction in LPS 
week 1 & 3, 65.9% 
reduction at week 5 
(P<0.005) 
- - Mini et al., 2008 
8  6 months  451 adults with 
chronic insomnia 
 
Reduced LPS 
consistently 
- - Mayer et al., 2009 
 6 weeks  20 healthy peri- and 
post-menopausal 
women 
Reduced  LPS Increased  Increased  Dobkin et al., 2009 
4, 8 and16 24 weeks 190 adults with 
chronic insomnia 
 
 Increased 
 
Increased up to 20 
weeks and then it 
was maintained 
Uchiyama et al., 
2011  
4 and 8 2 weeks 1130 adults Reduced SOL with       
8 mg only 
Increased in 
the first week 
Increased Uchimura et al., 2011 
4 and 8 2 nights 65 patients with 
insomnia 
Reduced  LPS Increased sleep 
quality 
Increased Kohsaka et al., 2011 
Table 1. Ramelteon’s beneficial effects in sleep disorders: primary insomnia
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In a study conducted on 75 healthy human subjects, the
administration of ramelteon at doses of 1, 2, 4 and 8 mg
for 6 days caused significant advancement of dim light
melatonin offset (Richardson et al., 2008). Melatonergic
hypnotic and chronobiotic drug ramelteon has a unique
place in development of novel drugs for treatment of
insomnia (Srinivasan et al., 2009).
Interestingly, a recent randomized, placebo-
controlled study suggested that ramelteon can be also
beneficial for treatment of ambulatory bipolar I disorder
patients suffering from manic symptoms and sleep
disturbances. Twenty-one outpatients with bipolar I
disorder with mild-to-moderate manic symptoms and sleep
disturbance were randomized to receive either ramelteon
(N=10) or placebo (N=11) in an 8-week, double-blind,
fixed-dose (8 mg/day) study. Ramelteon and placebo had
similar rates of reduction in ratings of symptoms of
insomnia, mania, and global severity of illness. However,
ramelteon was associated with improvement in a global
rating of depressive symptoms. It was also well tolerated
and associated with no serious adverse events (McElroy
et al., 2011).
5. Agomelatine, depressive disorders and
insomnia
Depressive disorders are associated with sleep
disturbances. In these disorders insomnia is not a
consequence or an accompanying phenomenon but rather
represents a major triggering factor for the development
of depressive symptoms. Sleep disturbances occur in the
preceding as well as during the illness period of major
depressive disorders or bipolar disorders. Depressed
patients experience difficulty in falling asleep, staying
asleep and manifest early morning awakening (Kupfer,
2006). Agomelatine, a melatonergic drug developed by
Servier Laboratories (France), is a naphthalenic compound
chemically designated as [N-[2-(7-methoxynaphth-1-yl)
acetamide]. It has high affinity for MT
1
/MT
2
 melatonergic
receptors (Yous et al., 1992) and also acts as a 5-HT
2C
receptor antagonist (Millan et al., 2003). In the study on
the use of agomelatine (25 mg/day) on 165 patients and
by using Leeds Sleep Evaluation Questionnaire (LSEQ)
it was found that agomelatine caused earlier and greater
improvements on the criteria of “getting into sleep”, and
quality of sleep (Guilleminault, 2005). By using
polysomnography studies it was noted that use of
agomelatine increased sleep efficiency from day 7
onwards and reached significant effect on the 42nd day,
the last day of evaluation (P=0.05) (Quera-Salva et al.,
2005, 2007). The action of agomelatine in improving both
efficiency and quality of sleep is considered as one of the
major mechanisms by which agomelatine ameliorates
depressive symptoms of patients with major depressive
disorder (Srinivasan et al., 2010a).
6. Conclusion
Melatonin exhibits both hypnotic and chronobiotic
properties and thus has been used for inducing sleep and
for treating sleep disorders of children, adults and elderly
people. The results of endogenous melatonin’s action in
insomnia have not been consistent due to its short-half
life and rapid metabolism.
Ramelteon (Rozerem®) and agomelatine, the
melatonergic drugs with rapid onset and sustained actions,
have been effective in treating sleep disorders and or sleep
disturbances associated with depressive disorders. The
melatonergic agonist ramelteon has shown promising
results in the treatment and management of insomnia as
revealed in the number of clinical trials that were
undertaken in Europe, USA and Japan. This melatonergic
drug, by acting through MT
1
 and MT
2
 melatonergic
receptors in brain, particularly the SCN, has demonstrated
superior efficacy in promoting sleep with rapid onset of
action. Moreover, it did not exhibit any adverse side effects
associated with the use of benzodiazepine and non-
benzodiazepine sedative drugs that are in use today.
Ramelteon exerts a promising effect on sleep by
amplifying day/night differences in alertness and sleep
quality and by displaying effective sleep inducing effect.
Because they act in a natural way in promoting sleep,
their long-term use is not associated with any side effects
like dependency, next-day hangover, memory impairment,
cognitive dysfunction or psychomotor retardation.
Agomelatine, the melatonergic antidepressant, is effective
in treating patients with major depressive disorders and
other mood disorders and it is attributed partly to its
property of improving sleep quality and efficiency.
Melatonergic drugs have a place in treatment of sleep
disorders, and large clinical trials are needed to prove their
efficacy and long term safety.
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